Predicting Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients

• Status: Completed
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment.

The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the most severe ventilatory control instability (strongest chemoreflex response to carbon dioxide; highest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: David Andrew Wellman
• Collaborators: American Heart Association; National Institutes of Health (NIH)
• Treatments: Acetazolamide

Criteria

Inclusion Criteria (Heart failure patients)

• Left ventricular ejection fraction (EF) <50%, or heart failure with preserved EF

• Age 18-89

Exclusion Criteria:

• severe obstructive respiratory disease

• unstable heart failure status

• recent use of positive airway pressure therapy

• current use of opioids, benzodiazepines

• severe kidney disease

• severe anemia